Metraipolis › archive › dc_dda3ef3240cf
Rasburicase vs. allopurinol: mortality in hematological malignancies post anti-hyperuricemic therapy - real-world study — Europe PMC PMID:41225055
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41225055
- DOI
- 10.1007/s00520-[numero omesso]-y
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T14:16:39.012Z
- SHA-256 of the archived text
f63c802a70e61f418e4b52fbacc9fc39f3be69afdad892ec549f25318b993302- Stable URL of this page
https://metraipolis.com/documento/dc_dda3ef3240cf
How to cite
Rasburicase vs. allopurinol: mortality in hematological malignancies post anti-hyperuricemic therapy - real-world study — Europe PMC PMID:41225055 — Europe PMC (en), https://europepmc.org/article/MED/41225055 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_dda3ef3240cf (Metraipolis archive dc_dda3ef3240cf, sha256 f63c802a70e61f418e4b52fbacc9fc39f3be69afdad892ec549f25318b993302)
BibTeX
@misc{dcdda3ef3240cf,
title = {Rasburicase vs. allopurinol: mortality in hematological malignancies post anti-hyperuricemic therapy - real-world study — Europe PMC PMID:41225055},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41225055},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_dda3ef3240cf; sha256 f63c802a70e61f418e4b52fbacc9fc39f3be69afdad892ec549f25318b993302},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41225055. Agents can read the archived copy with the MCP tool read_document.